Clinical Significance of the Detection of Antinuclear Antibodies in Patients with Acute Hepatitis A
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The findings of several recent studies suggest that antinuclear antibodies (ANAs) are frequently detected in patients with acute hepatitis A (AHA). However, the clinical significance of a positive ANA test remains uncertain. This study was performed to evaluate the clinical significance of ANAs in AHA patients. Methods: All patients admitted with AHA were consecutively enrolled in this study. An ANA assay was performed by indirect immunofluorescence during hospitalization. ANA positivity was defined as an ANA titer ≥1:80. The peak international normalized ratio (INR), peak alanine aminotransferase (ALT) and peak bilirubin levels were assessed over the duration of the hospitalization, and the incidence of AHA complications was evaluated. Results: A total of 422 patients were enrolled in this study (age, 31±7 years), of which 260 (61.6%) were men. ANAs were detected in 179 AHA patients (42.4%). The proportion of ANA-positive patients varied significantly with AHA status on the day of the ANA assay (4.7% during the prodromal period vs 52.1% during the icteric or recovery period, p<0.001) and sex (56.2% in women vs 33.8% in men, p<0.001). The ANAs became undetectable in all ANA-positive patients within 3 months. The incidence of complications, including mortality, fulminant hepatic failure, renal dysfunction, relapse, and cholestatic hepatitis, did not differ significantly between ANA-positive and ANA-negative patients. Conclusions: ANAs were detected frequently and transiently in patients with AHA, especially after their peak-ALT day. The presence of ANAs may not be associated with the clinical outcome of AHA, but simply with AHA status on the ANA assay day.
Abstract
Background/Aims: The findings of several recent studies suggest that antinuclear antibodies (ANAs) are frequently detected in patients with acute hepatitis A (AHA). However, the clinical significance of a positive ANA test remains uncertain. This study was performed to evaluate the clinical significance of ANAs in AHA patients. Methods: All patients admitted with AHA were consecutively enrolled in this study. An ANA assay was performed by indirect immunofluorescence during hospitalization. ANA positivity was defined as an ANA titer ≥1:80. The peak international normalized ratio (INR), peak alanine aminotransferase (ALT) and peak bilirubin levels were assessed over the duration of the hospitalization, and the incidence of AHA complications was evaluated. Results: A total of 422 patients were enrolled in this study (age, 31±7 years), of which 260 (61.6%) were men. ANAs were detected in 179 AHA patients (42.4%). The proportion of ANA-positive patients varied significantly with AHA status on the day of the ANA assay (4.7% during the prodromal period vs 52.1% during the icteric or recovery period, p<0.001) and sex (56.2% in women vs 33.8% in men, p<0.001). The ANAs became undetectable in all ANA-positive patients within 3 months. The incidence of complications, including mortality, fulminant hepatic failure, renal dysfunction, relapse, and cholestatic hepatitis, did not differ significantly between ANA-positive and ANA-negative patients. Conclusions: ANAs were detected frequently and transiently in patients with AHA, especially after their peak-ALT day. The presence of ANAs may not be associated with the clinical outcome of AHA, but simply with AHA status on the ANA assay day.
참고문헌 (28)
- Berlin T, "Autoantibodies in nonautoimmune individuals during infections", Ann N Y Acad Sci, 1108, pp.584~593 (2007)
- Andersen P, "Smooth-muscle antibodies and other tissue antibodies in cytomegalovirus infection", Clin Exp Immunol, 22, pp.22~29 (1975)
- Andersen P, "Correlation of smooth-muscle and nuclear antibodies in normal subjects", Clin Exp Immunol, 27, pp.74~77 (1977)
- Muratori P, "Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C", Clin Infect Dis, 40, pp.501~507 (2005)
- Lenzi M, "Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort", Gut, 45, pp.435~441 (1999)
- Cassani F, "Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile", Hepatology, 26, pp.561~566 (1997)
- Peng YC, "Expression and clinical significance of antinuclear antibody in hepatitis C virus infection", J Clin Gastroenterol, 33, pp.402~406 (2001)
- Hsieh MY, "Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C", J Clin Pathol, 61, pp.333~337 (2008)
- Stroffolini T, "Does an ‘autoimmune’ profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey", J Viral Hepat, 11, pp.257~262 (2004)
- Williams MJ, "Autoantibodies in chronic hepatitis C virus infection and their association with disease profile", J Viral Hepat, 16, pp.325~321 (2009)
- Song D, "vaccination in Korea", Bull Int Union Tuberc, 47(Suppl 2), pp.165~167 (1972)
- Gutierrez A, "Transient positivity of antinuclear and anti-smooth muscle antibodies in hepatitis A virus infection", J Hepatol, 24, pp.123~ (1996)
- Moon HW, "High prevalence of autoantibodies in hepatitis A infection: the impact on laboratory profiles", J Clin Pathol, 62, pp.786~788 (2009)
- Vento S, "Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals", Lancet, 337, pp.1183~1187 (1991)
- Rahaman SM, "Idiopathic autoimmune chronic hepatitis triggered by hepatitis A", Am J Gastroenterol, 89, pp.106~108 (1994)
- Huppertz HI, "Autoimmune hepatitis following hepatitis A virus infection", J Hepatol, 26, pp.204~208 (1995)
- Skoog SM, "Autoimmune hepatitis preceded by acute hepatitis A infection", Am J Gastroenterol, 97, pp.1568~1569 (2002)
- Hilzenrat N, "Autoimmune hepatitis in a genetically susceptible patient: is it triggered by acute viral hepatitis A", Dig Dis Sci, 44, pp.1950~1952 (1999)
- Grunhage F, "Autoimmune hepatitis: sequel of a relapsing hepatitis A in a 75-year-old woman", Digestion, 70, pp.187~191 (2004)
- Sherlock S, "Viral hepatitis: general features, hepatitis A, hepatitis E and other viruses, In Diseases of the liver and biliary system. 11th ed.", pp.267~283 (2002), Blackwell Science
- Tong MJ, "Clinical manifestations of hepatitis A: recent experience in a community teaching hospital", J Infect Dis, 171(Suppl 1), pp.S15~S18 (1995)
- Holborow EJ, "Immunofluorescent detection of autoantibodies in the sera of acute infective hepatitis patients", Ann N Y Acad Sci, 177, pp.214~217 (1971)
- Yoon YK, "Epidemiological and genetic analysis of a sustained community-wide outbreak of hepatitis A in the Republic of Korea, 2008: a hospital-based case-control study", J Clin Virol, 46, pp.184~188 (2009)
- Seligmann M, "Studies on antinuclear antibodies", Ann N Y Acad Sci, 124, pp.816~832 (1965)
- Svec KH, "Age-related antinuclear factors: immunologic characteristics and associated clinical aspects", Arthritis Rheum, 10, pp.509~516 (1967)
- Shu S, "and titers of antinuclear, antismooth muscle, and other autoantibodies in blood donors", J Lab Clin Med, 86, pp.259~265 (1975)
- McCarthy M, "The gender gap in autoimmune disease", Lancet, 356, pp.1088~ (2000)
- Whitacre CC, "Sex differences in autoimmune disease", Nat Immunol, 2, pp.777~780 (2001)